(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS) on Monday announced additional data from the expansion cohorts in the Phase 2 trial of SLS009 in patients with relapsed/refractory acute myeloid leukemia.
The open-label, single-arm, multi-center study evaluated the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg.
In the 60 mg dose cohort patients were randomized into either a 60 mg dose once per week or a 30 mg dose two times per week, the biopharmaceutical company added.
The findings noted that the median overall survival in the 30 mg BIW group has not yet been reached but exceeds 7.7 months at latest follow-up, marking a milestone as expected mOS is historically around 2.5 months.
Additionally, the overall response rate in patients with acute myeloid leukemia with myelodysplasia related changes prospectively enrolled in two expansion cohorts was 56 percent, exceeding the prespecified target response rate of 33 percent.
SELLAS's stock is currently moving down 1.75 percent, to $1.13 on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
